MiMedx Group, Inc. reported $355M of revenue over the trailing twelve months, −2.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $355M (to Q2 2026). Net income: $6.2M, trailing twelve months to Q2 2026. Free cash flow: $45M, trailing twelve months to Q2 2026. Operating margin: −4.6%, trailing twelve months to Q2 2026.

MDXGMiMedx Group, Inc.

Healthcare

$4.61-37% 1Y

$4.61

$3.0952 weeks$7.96

MDXG as reported

MiMedx Group, Inc. reported $355M of revenue over the trailing twelve months, −2.4% on the year before. 11 reported series are charted on this page, each one as filed.

$355M

Revenue, trailing twelve months · to Q2 2026 · −2.4% against the twelve months before

Net income: $6.2M
Net income · −81% year on year · trailing twelve months to Q2 2026
Free cash flow: $45M
Free cash flow · −22% year on year · trailing twelve months to Q2 2026
Operating margin: −4.6%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MDXG, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$355M	−2.4%	Q2 2026
Net income	$6.2M	−81%	Q2 2026
EPS	$0.04	−81%	Q2 2026
Gross margin	77%	n/a	Q2 2026
Operating margin	−4.6%	n/a	Q2 2026
Net margin	−3.5%	n/a	Q2 2026
ROE	13%	n/a	Q2 2026
ROA	9.8%	n/a	Q2 2026
ROIC	30%	n/a	Q2 2026
Free cash flow	$45M	−22%	Q2 2026
P/E	115	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.